A observational study for safety and efficacy of Fulvestrant 500mg in postmenopausal patients with ER positive advanced or recurrent breast cancer after prior endocrine treatment. (SBCCSG-29)
Phase 2
Recruiting
- Conditions
- ocally advanced or metastatic breast cancer
- Registration Number
- JPRN-UMIN000009110
- Lead Sponsor
- Saitama Breast Cancer Clinical Study Group(SBCCSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1.Current or prior double cancer within 5 years. 2.Non-invasive breast cancer. 3.Inflammatory breast cancer. 4.An existing serious, uncontrolled cardiac disease. 5.Brain metastasis.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to treatment failure(TTF)
- Secondary Outcome Measures
Name Time Method Overall survival(OS), Clinical benefit rate(CBR), Response rate(RR), Safety